Nov 8 (Reuters) - Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period since the administration of the drug in a late-stage trial. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
973.8 USD | +0.60% | +1.76% | +10.87% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.87% | 105B | |
+3.91% | 109B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B | |
+295.70% | 8.12B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron's antibody therapy shows long-term protection against COVID-19